Vetoquinol: Double-digit Growth In 2021
20 Janvier 2022 - 7:45PM
Business Wire
- Total Group Sales: €521 million (up 21.9% as
reported)
- Annual Sales of Essential products: €296 million (up
34.0% as reported)
Regulatory News:
Matthieu Frechin, CEO of Vetoquinol (Paris:VETO), said:
"In a still uncertain sanitary environment, our business grew by
21.9%, outperforming the market in all our geographical areas. At
the heart of our strategy, sales of Essential products increased by
34% on a reported basis. Their development was perfectly balanced
between organic growth (+17%), which demonstrates our ability to
develop the market share of our existing brands, and external
growth with the contribution of the Drontal® and Profender® brands
(+17%) acquired in 2020.
This momentum illustrates the soundness of our hybrid growth
strategy based on the development of our Essentials portfolio and
targeted external growth operations; we are confident in the future
and in the profitable growth prospects of our laboratory."
Vetoquinol laboratory recorded sales of €521 million for the
year 2021, up 21.9% as reported and up 22.3% at constant exchange
rates.
At the end of December 2021, sales of Essential products
amounted to €296 million, up 33.3% at constant exchange rates.
Essential products continued their growth momentum, driven by the
ongoing development of the existing portfolio and by the
contribution of Drontal® and Profender® products. Essential
products accounted for 56.7% of the 2021 laboratory's sales (2020:
51.6%).
Sales of companion animal products amounted to €335 million and
represented 64% of total Vetoquinol sales. They increased by 30.4%
as reported and at constant exchange rates, benefiting from the
contribution of Drontal® and Profender® products. Sales of
production animal products amounted to €186 million, up 9.2% as
reported and up 10.0% at constant exchange rates.
All strategic territories grew at constant exchange rates in
2021: +23.5% in Europe, +22.6% in the Americas and +18.0% in
Asia/Pacific.
For the year 2021, the Group recorded a negative currency impact
of €1 million (-0.3%), mainly due to the decrease of the Brazilian
Real and the US Dollar.
In Q4 2021, the Vetoquinol Group recorded sales of €134
million, up 14.3% as reported and up 11.3% at constant exchange
rates compared to the same period last year. All strategic
territories grew, with sales up 7.2% as reported in Europe, 17.2%
in the Americas and 33.1% in Asia/Pacific. Sales of Essential
products continued to be strong with organic growth of 20.1%.
Covid-19 health situation as of January 20, 2022
The Vetoquinol laboratory continues to rigorously manage the
health situation related to Covid-19 and works to guarantee the
safety and health of its employees, while aiming to maintain
industrial activity, the continuation of the Group's projects and
the supply to its customers without interruption.
Vetoquinol's financial structure at December 31, 2021 remains
solid and cash flow generation continued in the second half of
2021. The audit of Vetoquinol's accounts is in progress at the date
of this release.
€m
2021
2020
Change (reported data)
Change (constant exchange
rates)
Organic growth
Q1 sales
127.9
103.4
+23.8%
+28.3%
+11.7%
Q2 sales
127.4
92.7
+37.3%
+39.2%
+23.8%
Q3 sales
132.3
114.4
+15.7%
+14.3%
+10.0%
Q4 sales
133.7
117.0
+14.3%
+11.3%
+11.3%
Annual sales
521.3
427.5
+21.9%
+22.3%
+13.7%
Next update: 2021 Annual Results, March 24th, 2022 before
market open
ABOUT VETOQUINOL
Vetoquinol is a leading global animal health company that
supplies drugs and non-medicinal products for the livestock (cattle
and pigs) and pet (dogs and cats) markets.
As an independent pure player, Vetoquinol designs, develops and
sells veterinary drugs and non-medicinal products in Europe, the
Americas and the Asia Pacific region.
Since its foundation in 1933, Vetoquinol has pursued a strategy
combining innovation with geographical diversification. The Group’s
hybrid growth is driven by the reinforcement of its product
portfolio coupled with acquisitions in high potential growth
markets. Vetoquinol employed 2,546 people as of December 31,
2021.
Vetoquinol has been listed on Euronext Paris since 2006 (symbol:
VETO).
The Vetoquinol share is eligible for the French PEA and PEA-PME
personal equity plans.
ANNEX
ALTERNATIVE PERFORMANCE INDICATORS
Vetoquinol Group management considers that these indicators,
which are not defined by IFRS, provide additional information that
is relevant for shareholders seeking to analyze underlying trends
and Group performance and financial position. They are used by
management for performance analysis.
Essentials products: The products referred to as
“Essentials” comprise veterinary drugs and non-medical products
sold by the Vetoquinol Group. They are existing or potential
market-leading products designed to meet the daily requirements of
vets in the companion animal or livestock sector. They are intended
for sale worldwide and their scale effect improves their economic
performance.
Constant exchange rates: Application of the previous
period’s exchange rates to the current financial year, all other
things remaining equal.
Like-for-like (LFL) growth: Year-on-year sales growth in
terms of volume and/or price at constant consolidation scope and
exchange rates.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220120005686/en/
FOR MORE INFORMATION, CONTACT:
VETOQUINOL
Investor Relations Fanny Toillon Tel.: +33 (0)3 84
62 59 88 relations.investisseurs@vetoquinol.com
KEIMA COMMUNICATION
Investor & Media Relations Emmanuel Dovergne
Tel.: +33 (0) 1 56 43 44 63 emmanuel.dovergne@keima.fr
Vetoquinol (EU:VETO)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
Vetoquinol (EU:VETO)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024